Estimated first-year costs of prostaglandin analogs with/without adjunctive therapy for glaucoma management: A United States perspective

Current Medical Research and Opinion

Volumn 23, Issue 11, 2007, Pages 2867-2875

  Schmier, Jordana K ^a   Covert, David W ^b   Robin, Alan L ^c  

^a EXPONENT INC   (United States)

^b ALCON RESEARCH LTD   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

Author keywords

Costs and cost analysis; Drug therapy; Glaucoma; Prostaglandins

Indexed keywords

BIMATOPROST; BRIMONIDINE; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; PROSTAGLANDIN DERIVATIVE; TIMOLOL; TRAVOPROST;

ADULT; AGED; BILLING AND CLAIMS; CONTROLLED STUDY; COST MINIMIZATION ANALYSIS; DRUG COST; FEMALE; FOLLOW UP; GLAUCOMA; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; OUTPATIENT CARE; REVIEW; UNITED STATES;

COHORT STUDIES; DRUG COSTS; GLAUCOMA, OPEN-ANGLE; HUMANS; INSURANCE CLAIM REVIEW; PROSTAGLANDINS; UNITED STATES;

EID: 36348939280     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X233287     Document Type: Review

References (28)

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90:262-7
2. Friedman DS, Wolfs RC, O'Colmain BJ, et al. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol 2004;122:532-8
3. American Academy of Ophthalmology. Preferred Practice Pattern. Primary Open-Angle Glaucoma. Limited Revision. San Francisco, CA: American Academy of Ophthalmology, 2003
4. Tielsch JM, Sommer A, Katz J, et al. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. JAMA 1991;17;266:369-74
5. Ntim-Amponsah CT, Amoaku WM, Ofosu-Amaah S, et al. Prevalence of glaucoma in an African population. Eye 2004;18:491-7
6. Leske MC, Connell AM, Wu SY, et al. Incidence of open-angle glaucoma: the Barbados Eye Studies. The Barbados Eye Studies Group. Arch Ophthalmol 2001;119:89-95
7. Quigley HA, West SK, Rodriguez J, et al. The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER. Arch Ophthalmol 2001;119:1819-26
8. Varma R, Ying-Lai M, Francis BA, et al. Prevalence of open-angle glaucoma and ocular hypertension in Latinos: the Los Angeles Latino Eye Study. Ophthalmology 2004;111:1439-48
9. Klein BE, Klein R, Sponsel WE, et al. Prevalence of glaucoma. The Beaver Dam Eye Study. Ophthalmology 1992;99:1499-504
10. Schmier JK, Halpern MT, Jones ML. The economic implications of glaucoma: a literature review. PharmacoEconomics 2007;25:287-308
11. Covert D, Robin AL. Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost. Curr Med Res Opin 2006;22:971-6
12. Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology 2005;112:863-8
13. Denis P, Covert D, Realini A. Travoprost in the management of open-angle glaucoma and ocular hypertension. Clin Ophthalmol 2007;1:11-24
14. Gold MR, Siegel JE, Russel LB, et al., eds. Cost-effectiveness in Health and Medicine. New York: Oxford University Press, 1996
15. Drummond M, Manca A, Sculpher M. Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies. Int J Technol Assess Health Care 2005;21:165-71
16. Goldberg LD, Walt J. Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost effectiveness of bimatoprost compared with other medications. PharmacoEconomics 2006;24:251-64
17. Fremont AM, Lee PP, Mangione CM, et al. Patterns of care for open-angle glaucoma in managed care. Arch Ophthalmol 2003;121:777-83
18. Wolters Kluwer Health Price Rx™ Drug Price and Reference Tool. www.wkhealth.com [Last accessed February 2007]
19. Practice Management Information Corporation. Medical Fees in the United States. Los Angeles, CA: Practice Management Information Corporation, 2006
20. Fiscella RG, Green A, Patuszynski DH, et al. Medical therapy cost considerations for glaucoma. Am J Ophthalmol 2003;136:18-25
21. Platt R, Reardon G, Mozaffari E. Observed time between prescription refills for newer ocular hypotensive agents: the effect of bottle size. Am J Ophthalmol 2004;137(1 Suppl):S17-23
22. Fiscella R, Wilensky JT, Chiang TH, et al. Efficiency of instillation methods for prostaglandin medications. J Ocul Pharmacol Ther 2006;22:477-82
23. Rouland JF, Berdeaux G, Lafuma A. The economic burden of glaucoma and ocular hypertension: implications for patient management: a review. Drugs Aging 2005;22:315-21
24. Schwartz GF, Platt R, Reardon G, et al. Accounting for restart rates in evaluating persistence with ocular hypotensives. Ophthalmology 2007;114:648-52
25. Friedman DS, Nordstrom B, Mozaffari E, et al. Glaucoma management among individuals enrolled in a single comprehensive insurance plan. Ophthalmology 2005;112:1500-4
26. Lee PP, Walt JG, Doyle JJ, et al. A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma. Arch Ophthalmol 2006;124:12-19
27. Traverso CE, Walt JG, Kelly SP, et al. Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe. Br J Ophthalmol 2005;89:1245-9
28. Kobelt G. Health economics, economic evaluation, and glaucoma. J Glaucoma 2002;11:531-9